Qure.ai vs Abridge

By valuation, Abridge is the larger company at $5.3B versus $270M — a 19.6x difference. Size can also be measured by team: Qure.ai employs 250 people while Abridge has 120 employees.

Abridge has raised more in total funding at $800M, compared to Qure.ai's $123M — a gap of $677M. Combined, the two companies have completed 9 known funding rounds.

Abridge leads with an Awaira Score of 76/100, while Qure.ai sits at 70/100. That 6-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Qure.ai was founded by Prashant Warier in 2016. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology uses natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Qure.ai got there first, launching in 2016 — that's 2 years of extra runway. Abridge didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Qure.ai has about 250 employees; Abridge has about 120. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Qure.ai and Abridge compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.